🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression

Recruitingn/aAges 40 Years - 90 YearsAllAmsterdam UMC, location VUmc
NCT06206369 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The VASCULAID-RETRO study, within the broader VASCULAID project, aims to create artificial intelligence (AI) algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). The study plans to gather and analyze data from at least 5000 AAA and 6000 PAD patients, combining existing cohorts and retrospectively collected data. During this project, AI tools will be developed to perform automatic anatomical segmentation and analyses on multimodal imaging. AI prediction algorithms will be developed based on multisource data (imaging, medical history, -omics).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria AAA: * Males and females * 40-90 years old, * Infrarenal, juxtarenal, suprarenal, iliac aneurysms (defined as 1.5x its normal diameter), and mycotic aneurysms. * Starting AAA diameter \>3cm, * Patients that both have had or did not have interventions or ruptures. Exclusion Criteria AAA: * Patients with solely an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm. Inclusion Criteria PAD: * Males and females, * 40-90 years old, * All PAD patients; all Fontaine stages 1,2,3, and 4. Exclusion Criteria PAD: None
💊

What it tests

  • No intervention, retrospective study
📍

Where

6 sites
Hospital District of Helsinki and Uusimaa (HUS)
Helsinki, Finland
Asklepios kliniken hamburg
Hamburg, Germany
Amsterdam UMC
Amsterdam, Netherlands
University Hospital Center of São João
Porto, Portugal
University Clinical Centre of Serbia
Belgrade, Serbia
Oxford University Hospitals
Oxford, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy